ReviewPharmaceutics2021
Excipients in the Paediatric Population: A Review.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Parent-Reported Satisfaction, Perceived Child Acceptance, and Ease of Administration of a Strawberry-Flavoured Ibuprofen Suspension for Children: A Cross-Sectional Survey of Experienced Users in Germany.Journal of market access & health policy · 2026Article
- Evaluation of Ease of Use for Pediatric Medications Requiring Decapsulation, Dissolution, or Partial Dosing: A Questionnaire-Based Study in Japan.Therapeutic innovation & regulatory science · 2026Article
- Long-Acting Therapeutics in Pediatric Health: Bridging Innovation and Access.Clinical pharmacology and therapeutics · 2026Review
- Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of Levocarnitine.Pharmaceutical medicine · 2026Review
- Physicochemical evaluation of pediatric liquid medicines in Ghana: implications for cariogenicity and erosive potential.BMC oral health · 2026Article
- Age-Appropriateness of Oral Formulations Authorized for Pediatrics.Pharmaceutical research · 2026Article
- Ingredients to Mask the Aversive Taste of Medicines: Lessons from the Pharmaceutical and Food Industries and Home Remedies Adopted by Caregivers.Foods (Basel, Switzerland) · 2026Review
- Tricalcium Citrate Tetrahydrate TB as Filler in Direct Compression of Minitablets.AAPS PharmSciTech · 2026Article
- Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities.Pharmaceutics · 2026Review
- [Drug Excipients. Necessary, but not Harmless].Farmaceuticos comunitarios · 2025Review
- Choosing the "Ideal" Oral Dosage Form for Pediatric Patients: Parents' Perspectives on Children's Preferences with a Focus on Orodispersible Tablets.Children (Basel, Switzerland) · 2025Article
- Extemporaneous Compounding, Pharmacy Preparations and Related Product Care in the Netherlands.Pharmaceutics · 2025Review
- Metronidazole Suspension for Paediatric Use in Developing Countries: Formulation, Quality, and Stability.Pharmaceutics · 2025Article
- Review
- Compounding and stability studies of liquid oral formulations of beta-blockers (bisoprolol, betaxolol, and nadolol) for paediatric patients.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025Article
- Pediatric Orally Disintegrating Tablets (ODTs) with Enhanced Palatability Based on Propranolol HCl Coground with Hydroxypropyl-β-Cyclodextrin.Pharmaceutics · 2024Article
- Risperidone Pellets, PycnogenolPharmaceutics · 2024Article
- Application of Galenic Strategies for Developing Gastro-Resistant Omeprazole Formulation for Pediatrics.Children (Basel, Switzerland) · 2024Article
- Characterization of Prototype Gummy Formulations Provides Insight into Setting Quality Standards.AAPS PharmSciTech · 2024Article
- Development of Losartan Orally Disintegrating Tablets by Direct Compression: a Cost-Effective Approach to Improve Paediatric Patient's Compliance.AAPS PharmSciTech · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This theoretical study seeks to critically review the use of excipients in the paediatric population. This study is based on the rules and recommendations of European and American drug regulatory agencies. On the one hand, this review describes the most frequent excipients used in paediatric medicine formulations, identifying the compounds that scientific literature has marked as potentially harmful regarding the side effects generated after exposure. On the other hand, this review also highlights the importance of carrying out safety -checks on the excipients, which, in most cases, are linked to toxicity studies. An excipient in the compilation of paediatric population databases is expected to target safety and toxicity, as in the STEP database. Finally, a promising pharmaceutical form for child population, ODT (Orally Disintegrating Tablets), will be studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.